Update on the pharmacologic management of neonatal abstinence syndrome

Journal of Perinatology

Volumn 31, Issue 11, 2011, Pages 692-701

  Bio, L L ^a   Siu, A ^b   Poon, C Y ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b Department of Prosthodontics and Biomaterials   (United States)

Author keywords

buprenorphine; methadone; morphine; opioids; tincture of opium

Indexed keywords

ADENYLATE CYCLASE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPRENORPHINE; CLONIDINE; CODEINE; CORTICOSTEROID DERIVATIVE; CYCLIC AMP; DELTA OPIATE RECEPTOR; DEXTROPROPOXYPHENE; DIAMORPHINE; DIAZEPAM; FENTANYL; HYDROMORPHONE; KAPPA OPIATE RECEPTOR; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NORBUPRENORPHINE; OPIATE DERIVATIVE; OXYCODONE; PENTAZOCINE; PETHIDINE; PHENOBARBITAL; PLACEBO; THEOPHYLLINE;

AGITATION; ANOREXIA; ARTICLE; BLOOD ANALYSIS; BREAST FEEDING; BREAST MILK; CONSTIPATION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; HEART PALPITATION; HEART RATE; HUMAN; PATHOPHYSIOLOGY; PRENATAL EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; RISK ASSESSMENT; SIDE EFFECT; SOMNOLENCE; SUPRAVENTRICULAR TACHYCARDIA; SWEATING; TREMOR; URINALYSIS; WITHDRAWAL SYNDROME;

BENZODIAZEPINES; BUPRENORPHINE; CLONIDINE; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INFANT, NEWBORN; METHADONE; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; PHENOBARBITAL; PREGNANCY;

EID: 80455174651     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2011.116     Document Type: Article

References (37)

1. Vucinovic M, Roje D, Vucinovic Z, Capkun V, Bucat M, Banovic I. Maternal and neonatal effects of substance abuse during pregnancy: our ten-year experience. Yonsie Med J 2008; 49(5): 705-713.
2. Bauer CR, Langer JC, Shankaran S, Bada HS, Lester B, Wright LL et al. Acute neonatal effects of cocaine exposure during pregnancy. Arch Pediatr Adolesc Med 2005; 159(9): 824-834.
3. LaGasse LL, Wouldes T, Newman E, Smith LM, Shah RZ, Derauf C et al. Prenatal methamphetamine exposure and neonatal neurobehavioral outcome in the USA and New Zealand. Neurotoxicol Teratol 2011; 33(1): 166-175.
4. Schuckit Marc A. Opioid drug abuse and dependence. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J (eds). Harrison's Principles of Internal Medicine. 17th edn, McGraw-Hill: New York, http://www.accessmedicine. com/features.aspx, 2008.
5. Seligman NS, Almario CV, Hayes EJ, Dysart KC, Berghella V, Baxter JK. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. J Pediatr 2010; 157(3): 428-433, 433.e1.
6. AAP Committee on Drugs. Neonatal drug withdrawal. Pediatr 1998; 101(6): 1079-1088.
7. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr 1991; 118: 933-937.
8. Schempf AH. Illicit drug use and neonatal outcomes: A critical review. Obstet Gynecol Surv 2007; 62(11): 749-757.
9. Hunt RW, Tzioumi D, Collins E, Jeffery HE. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev 2008; 84: 29-35.
10. Ebner N, Rohrmeister K, Winklbaur B, Baewert A, Jagsch R, Peternell A et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007; 87(2-3): 131-138.
11. Parikh R, Hussain T, Holder G, Bhoyar A, Ewer AK. Maternal methadone therapy increases QTc interval in newborn infants. Arch Dis Child Fetal Neonatal Ed 2011; 96(2): F141-F143.
12. Schumacher Mark A, Basbaum Allan I, Way Walter L. Opioid analgesics and antagonists. In: Katzung BG, Masters SB, Trevor AJ (eds). Basic & Clinical Pharmacology 10th edn. McGraw-Hill: New York, (2007), http://www. accessmedicine.com/features.aspx.
13. Ostrea Jr EM, Knapp DK, Tannenbaum L, Ostrea AR, Romero A, Salari V et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr 2001; 138(3): 344-348.
14. Finnegan LP, Kron RE, Connaughton JF, Emich JP. Assessment and treatment of abstinence in the infant of the drug-dependent mother. Int J Clin Pharmacol Biopharm 1975; 12: 19-32.
15. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants. a pragmatic evaluation of its efficacy. Clin Pediatr 1975; 14: 592-594.
16. Green M, Suffet F. The neonatal narcotic withdrawal index: A device for the improvement of care in the abstinence syndrome. Am J Drug Alcohol Abuse 1981; 8: 203-213.
17. Ostrea EM. Infants of drug-dependent mothers In: Burg FD, Ingelfinger JR, Wald ER (eds). Current Pediatric Therapy, vol 14. WB Saunders: Philadelphia, PA, 1993; 800-801.
18. Zahorodny W, Rom C, Whitney W, Giddens S, Samuel M, Maichuk G et al. The neonatal inventory: A simplified score of newborn withdrawal. J Behav Pediatr 1998; 19: 89-93.
19. Jansson LM, Velez M, Harrow C. Methadone maintenance and lactation: A review of the literature and current management guidelines. J Hum Lac 2004; 20: 62-71.
20. CDC. Recommendations for prevention and control of Hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47(RR-19): 1-39.
21. HHS Blueprint for Action on Breastfeeding, US Department of Health and Human Services: Washington, D.C., 2000, pp, 12-13.
22. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on severity and outcome of neonatal abstinence syndromes among infants of drugdependent mothers. Pediatr 2006; 117: e1163-e1169.
23. Jansson LM, Choo R, Velez ML, Harrow C, Schroeder JR, Shakleya DM et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatr 2008; 121(1): 106-114.
24. Lexi-comp (internet). Hudson OH. Lexi-comp, Inc. 1976-2008. Buprenorphine, diazepam, methadone, morphine, opium tincture. (cited April 27, 2010). http://online.lexi.com/crlsql/servlet/crlonline.
25. Langerfeld S, Birkenfeld L, Herkenrath P, Müller C, Helmich M, Theisohn M. Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend 2005; 77: 31-36.
26. Madden JD, Chappel JN, Zuspan F, Gumpel J, Mejia A, Davis R. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol 1977; 127(2): 199-201.
27. Lainwala S, Brown ER, Weinschenk NP, Blackwell MT, Lagadorn JI. A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. Adv Neonatal Care 2005; 5(5): 265-272.
28. Kraft WK, Gibson E, Dysart K, Damle VS, LaRusso JL, Greenspan JS et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: A randomized trial. Pediatr 2008; 122: e601-e607.
29. Kuhlman Jr. JJ, Levine B, Johnson RE, Fudala PJ, Cone EJ. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93(4): 549-559.
30. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction 2011; 106(3): 574-580.
31. Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr 2002; 140(5): 561-564.
32. Jackson L, Ting A, Mckay S, Galea P, Skeoch C. A randomized controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed 2004; 89: F300-F304.
33. Potts AL, Larsson P, Eksborg S, Warman G, Lönnqvist P, Anderson BJ. Clonidine disposition in children; a population analysis. Pediatr Anesthe 2007; 17: 924-933.
34. Agthe AG, Kim GR, Mathias KB, Hendrix CW, Chavez-Valdez R, Jansson L et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: A randomized, controlled trial. Pediatrics 2009; 123(5): E849-e856.
35. Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2005; 3, Art No.: CD002053. doi:10.1002/14651858.CD002053.pub2.
36. The Joint Commission. Sentinel event alert: Preventing pediatric medication errors. Issue 39, 2008, http://www.jointcommission.org/assets/1/18/ SEA-39.PDF.
37. Levinson ML, Johnson CE. Stability of an extemporaneously compounded clonidine hydrochloride oral liquid. Am J Hosp Pharm 1992; 49(1): 122-125.